GIST
Oncology · 2007–2021
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ripretinib Treatment of advanced gastrointestinal stromal tumour (GIST) after failure of or intolerance to imatinib and sunitinib. | Mar 2021 | Not recommended | 98 individuals Life Raft Group · Medical Oncology Group |
| imatinib Change in pack size for gastrointestinal stromal tumor (GIST) treatment in metastatic and adjuvant settings. | Mar 2015 | Not recommended | unclear |
| imatinib Adjuvant treatment of patients at high risk of recurrence following complete resection of primary gastrointestinal stromal tumour (GIST). | Mar 2012 | Not recommended | no section in document |
| imatinib Adjuvant treatment for 12 months of adult patients at high risk of recurrence following complete resection of primary gastrointestinal stromal tumour (GIST). | Jul 2010 | Not recommended | no section in document |
| imatinib Adjuvant treatment for 12 months of adult patients at high risk of recurrence following complete resection of primary gastrointestinal stromal tumour (GIST)… | Jul 2010 | Not recommended | no section in document |
| sunitinib malate Initial and continuing treatment of metastatic or unresectable malignant gastrointestinal stromal tumour (GIST) after failure of imatinib mesylate due to… | Jul 2009 | Recommended with restriction | no section in document |
| sunitinib malate Treatment of adult patients with metastatic or unresectable gastrointestinal stromal tumour (GIST) after failure of imatinib mesylate due to resistance or… | Mar 2007 | Recommended | no section in document |
Who spoke
Life Raft Group · Medical Oncology Group
What the PBS pays
$17M in government benefit over 2024–25, across 30,402 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| imatinib | $8.6M |
| ripretinib | $7.9M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| imatinibImatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours | TA86 | recommended restricted | 2004-10 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.